Reuters: Regulatory News: UPDATE 1-Affymax, Takeda recall anemia drug Omontys after deaths

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-Affymax, Takeda recall anemia drug Omontys after deaths Feb 24th 2013, 18:21 Sun Feb 24, 2013 1:21pm EST TOKYO/WASHINGTON Feb 24 (Reuters) - U.S.-based Affymax Inc and Japan's Takeda Pharmaceutical Co said they are voluntarily recalling all lots of anemia treatment Omontys (peginesatide) in the United States due to reports of serious hypersensitivity reactions, including some deaths. As of Sunday, fatal reactions to the injection have been reported in about 0.02 percent of 25,000 patients after receiving their initial injection of the treatment, Affymax said in a statement. The drug is used to treat anemia in adult dialysis patients, and has resulted in reports of serious allergic reactions known as anaphylaxis in some recipients. The U.S. Food and Drug Administration on Sunday alerted healthcare providers about the recall, and said it had received 19 reports of anaphylaxis from dialysis centers in the United States. "Due to the severity of the public health risk, we want to be certain that healthcare providers stop using Omontys," said Howard Sklamberg, who heads the compliance office at the FDA's Center for Drug Evaluation and Research. Sklamberg said the agency is investigating the products and facilities related to the recall and will provide updates once it receives more information.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions